Low testosterone commonly affects older men. And while aging does reduce testosterone production, most treatments are too dangerous for casual, off-label use. In fact, many low-t therapies can have devastating, even life-threatening, side effects for men at any age. Many men who’ve taken testosterone boosters to improve their mood, libido and energy levels risk heart attacks or stroke during treatment. These serious cardiac events can result in death, causing families to lose their loved ones due to unnecessary medical treatments. Men who’ve had a cardiovascular event or relatives of deceased victims are now suing low testosterone therapy manufacturers, including AbbVie and Abbott Laboratories.
Low-T Victims Say Drug Makers Failed to Warn About Heart Attack Risks
Not sure if you’ve taken low testosterone therapy products? Some common low-t medications include:
- AndroGel
- Androderm
- Axiron
- Testim
In January 2014, the U.S. Food and Drug Administration announced a testosterone therapy safety investigation. This came after a November 2013 study in the Journal of the American Medical Association found older men with underlying heart disease had a 30% higher risk for stroke, heart attack and death while using low-t products. A second study found that younger men with preexisting heart disease also face a heightened risk for serious cardiovascular events. These medical studies may influence juries on future rulings involving low-T victims. In addition, deceased victims’ family members are filing wrongful death lawsuits against low testosterone treatment manufacturers.
What Low-T Victims Can Do
Men who’ve had a heart attack or stroke while using testosterone boosters may qualify for financial compensation. Earlier this year, a Chicago jury awarded $150 million in punitive damages to plaintiff Jesse Mitchell. To see if you may be entitled to a cash settlement, get your free compensation evaluation now. After you’ve submitted your information, an experienced advocate will contact you to discuss your compensation options.